N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Recruiting now · Phase 2

Conditions studied: High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma

In brief

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

Key facts

Study ID

NCT06528496

Run by

Memorial Sloan Kettering Cancer Center

People needed

45

Starts

2024-07-22

Expected to finish

2029-07-22

Last updated by the study team

2026-07-22

Who can join

Age: 2 and older, up to 19. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
• HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients >18 months old.
• No more than one prior cycle of HR-NB chemotherapy
• Age <19 years.
• Signed informed consent indicating awareness of the investigational nature of this treatment.

You may not qualify if…

• Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity >/= to grade 3
• °Organ dysfunction due to direct effects of primary tumor or metastatic disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., steroid- induced hyperglycemia or hypertension) will also not be considered in exclusion criteria
• Inability to comply with protocol requirements
• Pregnancy

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.